Corcept oncology chief sells 296 shares at $100.82

CORCEPT THERAPEUTICS INC (CORT) reported that Roberto Wandenkolk Vieira, President, Oncology, sold 296 shares of common stock on September 16, 2026 at $100.82 per share in an open-market transaction under a Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) reported that Roberto Wandenkolk Vieira, President, Oncology, sold 296 shares of common stock on September 16, 2026 at $100.82 per share in an open-market transaction under a Rule 10b5-1 trading plan. After the sale, he held 3,946 shares directly, including 1,347 unvested restricted stock award shares scheduled to vest in full on the one-year anniversary of each grant date subject to conditions.

Insider Trade Summary 10b5-1

Net Seller: 296 shares

Net Sell 1 txn

Insider Vieira Roberto Wandenkolk

Role President, Oncology

Sold 296 shs ($30K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	296	$100.82	$30K

Holdings After Transaction: Common Stock — 3,946 shares (Direct)

Footnotes (2)

1. F1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
2. F2. Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Key Figures

Shares sold: 296 shares Sale price per share: $100.82 per share Shares held after transaction: 3,946 shares +5 more

8 metrics

Shares sold 296 shares Open-market sale on September 16, 2026

Sale price per share $100.82 per share Common stock transaction on September 16, 2026

Shares held after transaction 3,946 shares Direct holdings following the September 16, 2026 sale

Unvested restricted stock awards 1,347 shares Included within the 3,946 shares held after the transaction

RSA grant on December 1, 2025 179 shares Unvested restricted stock award underlying shares

RSA grant on March 2, 2026 396 shares Unvested restricted stock award underlying shares

RSA grant on June 1, 2026 634 shares Unvested restricted stock award underlying shares

RSA grant on September 1, 2026 138 shares Unvested restricted stock award underlying shares

Key Terms

Rule 10b5-1 plan, restricted stock awards, unvested, vest

4 terms

Rule 10b5-1 plan regulatory

"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock awards financial

"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

unvested financial

"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person"

vest financial

"100% of the shares underlying the restricted stock awards will vest on the one-year anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CORT report for Roberto Wandenkolk Vieira?

Corcept reported that Roberto Wandenkolk Vieira sold 296 shares of common stock on September 16, 2026 in an open-market transaction at $100.82 per share, and continued to hold shares after the sale.

Was the CORT insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 17, 2026, which was in effect at the time of the September 16, 2026 transaction.

How many CORT shares does Roberto Wandenkolk Vieira hold after this transaction?

After the sale, Roberto Wandenkolk Vieira directly holds 3,946 shares of Corcept common stock, according to the filing’s post-transaction holdings disclosure.

What unvested restricted stock awards does the CORT officer have after the sale?

His 3,946-share holding includes 1,347 shares underlying unvested restricted stock awards: 179 from December 1, 2025; 396 from March 2, 2026; 634 from June 1, 2026; and 138 from September 1, 2026.

When will the CORT restricted stock awards vest for this officer?

The filing states that 100% of the shares underlying each restricted stock award will vest on the one-year anniversary of the respective grant date, provided the reporting person satisfies specified requirements.

What is Roberto Wandenkolk Vieira’s role at CORT?

The filing identifies Roberto Wandenkolk Vieira as an officer of Corcept Therapeutics Inc., serving as President, Oncology at the time of the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 07:54 PM Accepted by SEC EDGAR 09/18/2026 - 07:53 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vieira Roberto Wandenkolk

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Oncology

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S(1)		296	D	$100.82	3,946(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

2. Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Roberto Wandenkolk Vieira	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)